Replimune Group Inc. stocks have been trading down by -12.28 percent following negative sentiment around its latest clinical trial developments.
Live Update At 11:33:10 EDT: On Friday, April 24, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending down by -12.28%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Replimune Group Inc. is trading like a broken biotech story. REPL was changing hands around $7–$8 in late March, then the floor gave way in April after the FDA hit RP1 with another Complete Response Letter. The chart shows a brutal gap down from $8.05 on 2026/04/08 to a $5.89 close, then a further slide to $4.76 on 2026/04/10 as trading in REPL was halted.
The damage didn’t stop there. In the days after the news, REPL bled down into the low $2s, with recent closes between $1.70 and $2.85. That’s a classic post‑catalyst collapse where trapped longs rush for the exits and day traders hunt dead‑cat bounces. Intraday, REPL now grinds between roughly $2.45 and $2.60, with tight 5‑minute candles showing a stock in consolidation after heavy liquidation.
Fundamentally, Replimune is still pre‑revenue and deeply loss‑making. The latest quarterly numbers show about $70.9M in net loss, driven by $53.1M in research and $18.7M in G&A. Cash and short‑term investments sit near $269.1M, with working capital of roughly $230.3M and a strong current ratio around 5.6. That gives REPL runway, but returns on equity and assets are sharply negative, reminding traders this is a high‑burn, high‑risk biotech without approved products.
Why Traders Are Watching REPL After The FDA Shock
REPL is the kind of name momentum traders circle when the story breaks. Here, the story is the FDA’s second Complete Response Letter for RP1, also called vusolimogene oderparepvec, in combination with nivolumab for advanced melanoma after PD‑1 failure. Replimune disclosed that a new FDA review team reversed or contradicted prior feedback, now saying the single‑arm IGNYTE trial data are not enough to show effectiveness. That ripped out the heart of the accelerated‑approval narrative.
For months, many on the Street treated the BLA as a near‑term catalyst that might unlock value in REPL’s oncolytic immunotherapy platform. Instead, traders got a textbook downside surprise. The stock dropped almost 20% intraday on 2026/04/10 before trading was halted, then ultimately collapsed roughly 64% as the full impact sank in. Heavy volume on those sessions tells you funds weren’t just trimming; they were dumping.
The business fallout is just as important as the chart. Replimune says RP1 development is not viable without timely accelerated approval and plans to cut jobs and substantially scale back U.S. manufacturing operations. That turns REPL from a growth story into a restructuring story overnight. Cost cuts may slow the burn, but they also signal a smaller, less ambitious pipeline.
Wall Street has responded in kind. Cantor Fitzgerald, Piper Sandler, JPMorgan and HC Wainwright all moved to the sidelines or worse, with ratings at Neutral, Underweight, or outright Sell and a mean target around $4. HC Wainwright went from Buy to Sell, a full capitulation that tells traders former bulls no longer see a clean path to upside. For short‑term players, that shift in sentiment is fuel for both sharp bounces and vicious fades around any headline.
On top of that, legal clouds are gathering over REPL. Johnson Fistel is probing whether the company misled shareholders about fixing earlier FDA concerns, and Pomerantz LLP is investigating potential securities fraud after the 64% price collapse. Those headlines add another layer of uncertainty and help explain why some longer‑term holders are throwing in the towel instead of waiting for a turnaround.
More Breaking News
- MLI Stock Climbs As Mueller Industries Expands U.S. Copper Capacity
- GEV Stock Climbs As Traders Position For Earnings
- LEU Stock Rallies As Centrus Energy Ramps Massive Piketon Expansion
- BYND Stock Pops As Beyond Meat Steps Into Drinks And Breakfast
Conclusion
For active traders, REPL has now moved into the high‑risk, special‑situation bucket. The FDA’s rejection of the RP1 BLA, and the agency’s insistence that IGNYTE data are inadequate, leave Replimune with no clear regulatory path for its lead asset. The company’s own admission that RP1 development is not viable without accelerated approval, plus planned job cuts and scaled‑back U.S. manufacturing, underline how severe this pivot is.
At the same time, the balance sheet still shows more than $120M in cash and over $269M when you include short‑term investments, along with solid working capital. That gives REPL time to reassess strategy, but not a free pass. With net losses above $70M in the latest quarter and negative returns across equity and assets, management needs to prove there is life beyond RP1. Until then, the stock is going to trade on headlines, not on stable fundamentals.
Layer on multiple downgrades and ongoing law‑firm investigations, and you have a name where sentiment can swing wildly in both directions. This is exactly the type of chart traders on timothysykes.com study for volatility and pattern recognition — not for buy‑and‑forget holding. As Tim Sykes likes to remind his students, “Adapt or perish. Now as ever, nature’s merciless imperative.” As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. That mindset applies to trading REPL right now: stay nimble, cut losses fast, and treat every move as a trading setup, not a promise.
This coverage is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply